文献速递创伤骨科

PREPARE试验结果定向传播能否改变骨科手术消毒实践

Can a Targeted Dissemination Strategy of the PREPARE Trial Results Change Surgical Antiseptic Practice?
PubMed 文献 · Clin Orthop Relat Res · 2026-04-10

本研究在单中心一级创伤中心回顾性比较传播干预前后 extremity 骨折手术消毒剂选择,共分析4600例患者;干预后碘伏酒精消毒剂使用由0.8%升至86%(OR 765,95%CI 488–1197,p<0.001),并在17个月内维持稳定。

要点

  • 多点低成本的定向传播策略可使碘伏酒精消毒剂使用率从0.8%快速升至86%。
  • 干预后17个月内使用率保持稳定,无需额外传播措施。
  • 创伤专科培训医师的采用增幅(94.8%)高于未受专科培训者(34.7%)。

核心结论

  • 针对PREPARE试验结果的定向多点传播策略在本机构快速促成了碘伏酒精消毒剂作为骨折手术首选皮肤消毒剂,并在干预后17个月内维持。

研究设计与样本

  • 单中心城市一级学术创伤中心回顾性历史对照比较研究,纳入2020年1月至2025年7月接受肢体骨折手术且有手术消毒记录的患者,最终分析4600例(传播前3351例、过渡期49例、传播后1200例)。

主要发现

  • 碘伏酒精使用率由传播前的0.8%(27/3351)升至传播后的86%(1033/1200)(OR 765,95%CI 488–1197;p<0.001)。
  • 传播后17个月使用率无进一步传播措施下保持稳定(趋势检验p=0.20)。
  • 创伤专科培训医师采用增幅为94.8%,未受创伤专科培训医师为34.7%。
  • 医院消毒产品采购数据显示碘伏酒精需求上升、氯己定需求下降。

临床怎么用

  • 可采用外科医师主导、多学科团队教育、流程提醒与供应链保障等低成本 pragmatic 措施加速手术试验证据转化。

局限性

  • 为单中心回顾性历史对照研究,证据等级为III级;作者指出未来需评估实践改变的长期可持续性、手术部位感染结局及跨机构可推广性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PREPARE trial (Pragmatic Randomized trial Evaluating Pre-operative Alcohol skin solutions in Fractured Extremities), published in February 2024, demonstrated that 0.7% iodine povacrylex in 74% isopropyl alcohol reduced surgical site infections in patients with closed fractures compared with chlorhexidine gluconate in 70% isopropyl alcohol. Prior studies have shown that the translation of clinical trial findings into routine clinical practice and surgical procedures frequently takes longer than a decade, and strategies to accelerate implementation in orthopaedic surgery remain poorly defined. Engaging in a multifaceted implementation strategy with minimal barriers to entry for providers may be able to reduce this time to widespread adoption. QUESTIONS/PURPOSES: (1) Can the low-cost single-center dissemination efforts of the PREPARE trial results change antiseptic usage? (2) If a true practice change occurs, can the change be sustained over time without additional dissemination efforts? (3) Does the adoption of new evidence vary between fellowship-trained orthopaedic trauma surgeons and orthopaedic trauma surgeons who are not fellowship-trained? (4) What is the economic impact of a practice change to iodine povacrylex on hospital purchasing costs? METHODS: This was a retrospective, historically controlled comparative study of patients who underwent operative treatment of an extremity fracture at a single, urban, Level I academic trauma center before and after a dissemination effort aimed at increasing PREPARE trial awareness. A multifaceted dissemination strategy consisting of surgeon and nursing education, posted reminders, and supply chain support was implemented at the study site in February 2024. Patients were analyzed across three time periods: before dissemination (January 2020 to January 2024), during the transition (February 2024), and after dissemination (March 2024 to July 2025). An electronic medical record query identified patients with operative fracture management procedural codes who had a recorded antiseptic skin prep in the surgical flow sheet between January 2020 and July 2025. A total of 4822 patients were identified, and 222 duplicate entries were excluded, leaving 4600 patients for analysis (3351 before dissemination, 49 transitional, and 1200 after dissemination). To validate the completeness of our electronic health record query, we performed manual random sampling of monthly operative case logs, confirming that this query strategy successfully identified all patients with the relevant Current Procedural Terminology codes (that is, there were no exclusions for lack of antiseptic documentation). There were no differences in patient demographics, including sex, ethnicity, open fractures, or the distribution of upper and lower extremity fractures. Choice of surgical skin antiseptic was compared before and after dissemination using a log-binomial model. RESULTS: Dissemination efforts changed antiseptic use patterns with an immediate increase in iodine povacrylex use from 0.8% (27 of 3351) before intervention to 86% (1033 of 1200) after intervention (OR 765 [95% confidence interval 488 to 1197]; p < 0.001). This high level of use remained stable throughout the 17-month postintervention period without any additional dissemination efforts (p = 0.20 for trend). Adoption was higher among fellowship-trained trauma surgeons (94.8% increase) compared with surgeons without trauma fellowship training (34.7% increase). Hospital antiseptic product purchasing data, which reflect usage and restocking and were used as a secondary metric of practice change, also demonstrated an increase in iodine povacrylex demand and decline in chlorhexidine demand. CONCLUSION: A targeted and multifaceted dissemination strategy led to rapid adoption of iodine povacrylex for use as the preferred surgical skin antisepsis in fracture surgery at our institution, which was sustained over the 17-month postintervention period. This finding contrasts with a historically slow uptake of surgical trial evidence into clinical practice. Pragmatic, low-cost approaches such as surgeon leadership, team-based multidisciplinary education, workflow reminders, and supply chain readiness may help to accelerate translation of evidence into orthopaedic practice. Future studies should evaluate the long-term sustainability of practice changes, surgical site infection outcomes, and generalizability across institutions. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Nesbit SE, Hong I, O'Hara NN, et al. Can a Targeted Dissemination Strategy of the PREPARE Trial Results Change Surgical Antiseptic Practice? Clin Orthop Relat Res. 2026. PMID: 42008801. doi:10.1097/CORR.0000000000003925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。